The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
The Future of Precision Medicine in the Cure of Alzheimer’s Disease
Open accessAbstract
This decade has seen the beginning of ground-breaking conceptual shifts in the research of Alzheimer’s disease (AD), which acknowledges risk elements and the evolving wide spectrum of complicated underlying pathophysiology among the range of diverse neurodegenerative diseases. Significant improvements in diagnosis, treatments, and mitigation of AD are likely to result from the development and application of a comprehensive approach to precision medicine (PM), as is the case with several other diseases. This strategy will probably be based on the achievements made in more sophisticated research areas, including cancer. PM will require the direct integration of neurology, neuroscience, and psychiatry into a paradigm of the healthcare field that turns away from the isolated method. PM is biomarker-guided treatment at a systems level that incorporates findings of the thorough pathophysiology of neurodegenerative disorders as well as methodological developments. Comprehensive examination and categorization of interrelated and convergent disease processes, an explanation of the genomic and epigenetic drivers, a description of the spatial and temporal paths of natural history, biological markers, and risk markers, as well as aspects about the regulation, and the ethical, governmental, and sociocultural repercussions of findings at a subclinical level all require clarification and realistic execution. Advances toward a comprehensive systems-based approach to PM may finally usher in a new era of scientific and technical achievement that will help to end the complications of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The field of biomarkers is dominated by blood-based markers, including heart-type fatty acid-binding protein (HFABP), neurofilament light chain (NFL), neuron-specific enolase (NSE), total tau (t-Tau), phosphorylated tau (p-Tau), and monocyte chemoattractant protein-1 (MCP-1).”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [215]
In the citing paper
“These markers provide information about the underlying pathophysiology of AD and are crucial for detecting the disease, especially in those who have memory problems.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [215]
In the citing paper
“With the use of fluorodeoxyglucose (FDG)-PET, magnetic resonance imaging (MRI), and positron emission tomography (PET) imaging for the detection of tau and amyloid proteins, neuroimaging techniques have significantly advanced precision medicine in AD.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [215]
In the citing paper
“This allows for disease stratification and may even facilitate an earlier diagnosis [214,215].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED AND REPLACED: Nerve growth factor metabolic dysfunction in Down’s syndrome brains
Iulita, M. F., Carmo, S. D., Ower, A. K., Fortress, A. M., Aguilar, L. F., Hanna, M., Wısnıewskı, T., Granholm, A., Buhusi, M. C., Busciglio, J. A., et al. (2014) · Brain · doi:10.1093/brain/awt372 · Cited by 94
RetractedDermatologist-level classification of skin cancer with deep neural networks
Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017) · Nature · doi:10.1038/nature21056 · Cited by 14,362
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Research works printed but not linked: 1
- (2011). National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease; The National Academies Collection: Reports Funded by National Institutes of Health, National Academies Press (US).
Cited by
Sorted by citations
From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine
Toader, C., Șerban, M., Munteanu, O., Covache-Busuioc, R.-A., Enyedi, M., Ciurea, A. V., & Tătaru, C. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094271 · Cited by 161
Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer’s Disease Therapeutics
Dias, D., & Socodato, R. (2025) · Biomedicines · doi:10.3390/biomedicines13020279 · Cited by 60
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
“This allows for disease stratification and may even facilitate an earlier diagnosis [214,215].”
BackgroundAlzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches
Gholami, A. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137532 · Cited by 52
Resveratrol as a Therapeutic Agent in Alzheimer’s Disease: Evidence from Clinical Studies
Puranik, N., Kumari, M., Tiwari, S., Dhakal, T., & Song, M. (2025) · Nutrients · doi:10.3390/nu17152557 · Cited by 48
Metadata
- Authors
- Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., Faqih, Y. A. H., Rashid, H., Rashid, S. M., Bilal Ahmad, S., Alexiou, A., & Rehman, M. U.
- Affiliations
- King Saud bin Abdulaziz University for Health Sciences (SA)
- Jamia Hamdard (IN)
- Government Medical College (IN)
- Jazan University (SA)
- University of South Florida (US)
- Department of Pharmacy, Abu Areish General Hospital, Abu Areish 45911, Saudi Arabia
- Department of Emergency and Accident, Abu Areish General Hospital, Abu Areish 45911, Saudi Arabia
- Sher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir (IN)
- Division of Veterinary Biochemistry, Faculty of Veterinary Sciences and Animal Husbandry, Sher-e-Kashmir University of Agricultural Sciences and Technology (SKUAST-K), Srinagar 190006, India
- Novel Global Community Educational Foundation, Hebersham, NSW 2770, Australia
- Corresponding author
- Arafah, Azher
- Khan, Andleeb
- Rehman, Muneeb U.
- ORCID
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2023-01-25
- Volume
- 11
- Issue
- 2
- Pages
- 335
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC9953731
- OpenAlex
- W4317934405
- Cited by
- 133
- References
- 176
- Citations by year
- 2026: 31 · 2025: 54 · 2024: 41 · 2023: 7
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia (ISP22-19)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, precision medicine, neurodegenerative diseases, biomarkers, risk factors, pathophysiology, epigenetics, systems biology, disease natural history
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
